The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma
- 12 November 2025
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 152-165
Abstract
Anaplastic large cell lymphoma (ALCL), an aggressive T-cell malignancy, is marked by elevated expression of CD30 and the immune checkpoint molecule PD-L1. While CD30-directed chimeric antigen receptor (CAR) therapies have demonstrated clinical promise, therapeutic resistance remains a major hurdle. Here, we conducted integrated genome-wide CRISPR-Cas9 loss-of-function screens using CD30-specific CAR-engineered natural killer (CAR-NK) cells, alongside a complementary PD-L1 regulator screen, and uncovered a critical role for interleukin-1 receptor (IL-1R) signaling in modulating CAR therapy efficacy in both ALK⁺ and ALK⁻ ALCL. Mechanistically, IL-1R signaling drives an NFKBIZ – IL-17F – MAPK axis that sustains PD-L1 expression via an autocrine loop, while simultaneously inducing proinflammatory cytokines and chemokines that reinforce immune evasion and shape an immunosuppressive tumor microenvironment. Notably, NFKBIZ (IκBζ) emerges as a central transcriptional regulator orchestrating this immune suppression program upstream of IL-17F. Importantly, pharmacologic inhibition of IL-1R signaling significantly enhances the antitumor activity of CD30-specific CAR therapies both in vitro and in ALCL xenograft models. Collectively, our findings uncover a novel mechanism of immune resistance and nominate IL-1R blockade as a promising combinatorial strategy to improve CAR-based immunotherapy in ALCL.Keywords
This publication has 60 references indexed in Scilit:
- Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell LymphomaThe American Journal of Pathology, 2019
- Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− TumorsMolecular Therapy, 2019
- Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphomaAmerican Journal of Hematology, 2019
- Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphomaVirchows Archiv, 2018
- The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphomaLeukemia, 2018
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphomaLeukemia, 2017
- Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell LymphomaCancer Cell, 2015
- IκBζ regulates TH17 development by cooperating with ROR nuclear receptorsNature, 2010
- Structure and signalling in the IL-17 receptor familyNature Reviews Immunology, 2009
- Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 SignalingImmunity, 2009